Putnam Associates | Rare Disease AI Diagnostics Investment: Bet on Mult…

Minerva judgment

Recommend closing evidence gaps before phased investment: until three key uncertainties—bottleneck location, data representativeness, and clinical adoption capacity—are resolved, avoid irreversible resource lock-in from simultaneously betting heavily on multiple solutions

Decision owner in the teaching simulationCommittee Chair for Rare Disease Diagnostics Investment, in an independent educational simulation

Human-controlled next action

The committee chair directs the clinical evidence and patient access teams to submit concrete evidence on bottleneck location, data representativeness, and capacity absorption within a set deadline (e.g., one evaluation cycle) before finalizing the decision.

What would reverse the recommendation

If the referral and confirmatory-testing capacity bottleneck shown in F4 remains unresolved, phased investment should pause—even after evidence gaps are closed—to avoid resource misallocation

45 · Putnam Associates

Watch the actual operation film

Rare Disease AI Diagnostics Investment: Bet on Multiple Solutions Simultaneously, or Close Patient Journey, Evidence, and Clinical Adoption Gaps Before Phased Investment?

The Decision Room interface, case analysis, narration, captions and transcript are in English. The linked official source remains in its original language.

← Back to all 50 cases

Your browser cannot play this video. Download the MP4.Read the transcript

Official public source

Putnam Associates · AI diagnostic opportunity assessment

Evidence and endorsement boundary：Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.

Inspect the evidence, then test your own decision context.

See the first-use journey Back to all 50 cases →